About: Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study
Creator	Gao, Hong Chen, Christopher Yeung, Jonas Li, Ho Fong, Chi Ng, Ping Tsoi, Hong Wong, Chi Wong, Hwee Wong, Ka Yip, Kin
Source	Elsevier; Medline; PMC
abstract	Summary Background Acute stroke patients with large artery occlusive disease (LAOD) have a distinct pathophysiology and may respond differently to anticoagulation treatments. We compared the efficacy of a low-molecular-weight heparin (LMWH), nadroparin calcium, with aspirin in Asian acute stroke patients with LAOD. Methods Acute ischaemic stroke patients with onset of symptoms less than 48 h and LAOD (diagnosed by transcranial doppler imaging, carotid duplex scan, or magnetic resonance angiography) were recruited. Patients were randomly assigned to receive either subcutaneous nadroparin calcium 3800 anti-factor Xa IU/0·4 mL twice daily or oral aspirin 160 mg daily for 10 days, and then all received aspirin 80–300 mg once daily for 6 months. This study is registered at www.strokecenter.org/trials (number 493). Findings Among 603 patients recruited, 353 (180 LMWH, 173 aspirin) had LAOD (300 had intracranial LAOD only, 42 had both intracranial and extracranial disease, and 11 had extracranial disease only). The proportion of patients with good outcomes at 6 months (Barthel index ≥85) was 73% in the LMWH group and 69% in the aspirin group (absolute risk reduction 4%; 95% CI −5 to 13). Analysis of prespecified secondary outcome measures showed a benefit in outcome for LMWH versus aspirin on the modified Rankin scale dichotomised at 0–1 (odds ratio 1·55, 95% CI 1·02–2·35). Haemorrhagic transformation of infarct and severe adverse events were similar in both groups. Post-hoc analyses of patients without LAOD, and all treated patients, showed similar proportions with a good outcome in aspirin and LMWH groups (78% vs 79% and 73% vs 75%, respectively). Interpretation Overall, the results do not support a significant benefit of LMWH over aspirin in patients with LAOD. The benefits indicated in most outcome measures warrant further investigation into the use of anticoagulation for acute stroke in patients with large artery atherosclerosis, particularly in intracranial atherosclerosis.
has issue date	2007-05-31(xsd:dateTime)
bibo:doi	10.1016/s1474-4422(07)70079-0
bibo:pmid	17434095
has license	els-covid
sha1sum (hex)	fdfa931fdd9e83badf261cb48c582d2e90eeb94c
schema:url	https://doi.org/10.1016/s1474-4422%2807%2970079-0
resource representing a document's title	Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study
has PubMed Central identifier	PMC7185651
has PubMed identifier	17434095
schema:publication	The Lancet Neurology
resource representing a document's body	covid:fdfa931fdd9e83badf261cb48c582d2e90eeb94c#body_text
is schema:about of	named entity 'large' named entity 'heparin' named entity 'PATHOPHYSIOLOGY' named entity 'DISEASE' named entity 'HAVE' named entity 'ASIAN' named entity 'TREATMENT' named entity 'ACUTE' named entity 'OCCLUSIVE' named entity 'COMPARED' named entity 'BACKGROUND' named entity 'LARGE ARTERY' named entity 'LOW-MOLECULAR-WEIGHT HEPARIN' named entity 'DISTINCT' named entity 'COMPARED' named entity 'PATIENTS' named entity 'RANDOMISED STUDY' named entity 'ACUTE STROKE' named entity 'LOW-MOLECULAR-WEIGHT HEPARIN' named entity 'PATIENTS' named entity 'ASPIRIN' named entity 'ISCHAEMIC STROKE' named entity 'ASIAN' named entity 'ASPIRIN' named entity 'ANTICOAGULATION' named entity 'NADROPARIN CALCIUM' named entity 'DISEASE' named entity 'RESPOND' named entity 'OCCLUSIVE' named entity 'LARGE ARTERY' named entity 'CACY' named entity 'TREATMENTS' covid:arg/fdfa931fdd9e83badf261cb48c582d2e90eeb94c named entity 'compared' named entity 'compared' named entity 'disease' named entity 'nadroparin calcium' named entity 'anticoagulation' named entity 'Asian' named entity 'Asian' named entity 'aspirin' named entity 'respond' named entity 'systemic diseases' named entity 'stroke' named entity 'pregnancy test' named entity 'stroke' named entity 'subcutaneous' named entity 'anticoagulant' named entity 'Asia' named entity 'transcranial doppler' named entity 'stroke' named entity 'LMWH' named entity 'aspirin' named entity 'treatment group' named entity 'NIHSS' named entity 'Hong Kong' named entity 'ultrasound' named entity 'haemorrhagic' named entity '95% CI' named entity 'treatment allocation' named entity 'Hong Kong' named entity 'ect' named entity 'cation' named entity 'radiologists' named entity 'post-hoc analysis' named entity 'infarcts' named entity 'NIHSS' named entity 'subcutaneously' named entity 'SD 6' named entity 'severe acute respiratory syndrome' named entity 'intracerebral haemorrhage'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software